Search Results - "Konecny, G."

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions by Konecny, G E, Kristeleit, R S

“…Poly(ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombination (HR)-deficient cancers, including BRCA -mutated…”
Get full text

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I by Moore, K.N., Oza, A.M., Colombo, N., Oaknin, A., Scambia, G., Lorusso, D., Konecny, G.E., Banerjee, S., Murphy, C.G., Tanyi, J.L., Hirte, H., Konner, J.A., Lim, P.C., Prasad-Hayes, M., Monk, B.J., Pautier, P., Wang, J., Berkenblit, A., Vergote, I., Birrer, M.J.

“…Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the…”
Get full text

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis by Untch, M., von Minckwitz, G., Konecny, G.E., Conrad, U., Fett, W., Kurzeder, C., Lück, H.-J., Stickeler, E., Urbaczyk, H., Liedtke, B., Beckmann, M.W., Salat, C., Harbeck, N., Müller, V., Schmidt, M., Hasmüller, S., Lenhard, M., Nekljudova, V., Lebeau, A., Loibl, S., Fasching, P.A.

“…The objective of this study was to compare the effect of dose-intensified neoadjuvant chemotherapy with that of standard epirubicin plus cyclophosphamide…”
Get full text

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel±darbepoetin alfa in primary breast cancer—results at the time of surgery by Untch, M., Fasching, P.A., Konecny, G.E., von Koch, F., Conrad, U., Fett, W., Kurzeder, C., Lück, H.-J., Stickeler, E., Urbaczyk, H., Liedtke, B., Salat, C., Harbeck, N., Müller, V., Schmidt, M., Hasmüller, S., Lenhard, M., Schuster, T., Nekljudova, V., Lebeau, A., Loibl, S., von Minckwitz, G.

“…Preoperative chemotherapy is a recommended treatment of both primary operable and locally advanced breast cancer. Strategies to improve efficacy include the…”
Get full text

Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2 and RAD51C Status by Cunningham, J. M., Cicek, M. S., Larson, N. B., Davila, J., Wang, C., Larson, M. C., Song, H., Dicks, E. M., Harrington, P., Wick, M., Winterhoff, B. J., Hamidi, H., Konecny, G. E., Chien, J., Bibikova, M., Fan, J.-B., Kalli, K. R., Lindor, N. M., Fridley, B. L., Pharoah, P. P. D., Goode, E. L.

“…We evaluated homologous recombination deficient (HRD) phenotypes in epithelial ovarian cancer (EOC) considering BRCA1 , BRCA2 and RAD51C in a large…”
Get full text

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer by Konecny, G E, Santos, L, Winterhoff, B, Hatmal, M, Keeney, G L, Mariani, A, Jones, M, Neuper, C, Thomas, B, Muderspach, L, Riehle, D, Wang, H-J, Dowdy, S, Podratz, K C, Press, M F

“…Type II endometrial cancers (uterine serous papillary and clear cell histologies) represent rare but highly aggressive variants of endometrial cancer (EC)…”
Get full text

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells by Konecny, G E, Venkatesan, N, Yang, G, Dering, J, Ginther, C, Finn, R, Rahmeh, M, Fejzo, M Schoenberg, Toft, D, Jiang, S-W, Slamon, D J, Podratz, K C

“…In this study, we explore the therapeutic potential of lapatinib a selective inhibitor of both the EGFR and HER2 tyrosine kinases for the treatment of…”
Get full text

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells by Konecny, G E, Glas, R, Dering, J, Manivong, K, Qi, J, Finn, R S, Yang, G R, Hong, K-L, Ginther, C, Winterhoff, B, Gao, G, Brugge, J, Slamon, D J

“…Background: Here, we explore the therapeutic potential of dasatinib, a small-molecule inhibitor that targets multiple cytosolic and membrane-bound tyrosine…”
Get full text

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer by Davidson, T.M., Lebreton, C.L., Hendricksen, A.E. Wahner, Atkinson, H.J., Larson, M.C., Oberg, A.L., Provencher, D.M., Glaspy, J.A., Karlan, B.Y., Slamon, D.J., Konecny, G.E., Ray-Coquard, I.L.

“…IGF signaling has been implicated in the pathogenesis and progression of ovarian carcinoma (OC). Single agent activity and safety of ganitumab (AMG 479), a…”
Get full text

PARPi after PARPi in epithelial ovarian cancer by Essel, K.G., Behbakht, K., Lai, T., Hand, L., Evans, E., Dvorak, J., Ding, K., Konecny, G., Moore, K.N.

“…•The indication for treatment of ovarian cancer with a PARP inhibitor is expanding.•Prior exposure to a PARP inhibitor does not necessarily confer resistance…”
Get full text

Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer by Konecny, Gottfried, Pauletti, Giovanni, Pegram, Mark, Untch, Michael, Dandekar, Sugandha, Aguilar, Zuleima, Wilson, Cindy, Rong, Hong-Mei, Bauerfeind, Ingo, Felber, Margret, Wang, He-Jing, Beryt, Malgorzata, Seshadri, Ram, Hepp, Herrmann, Slamon, Dennis J.

“…Background: HER-2/neu, which encodes a receptor tyrosine kinase, is amplified and overexpressed in 20%–25% of human breast cancers. Such tumors are often…”
Get full text

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1 by Ryan, B.M., Konecny, G.E., Kahlert, S., Wang, H.-J., Untch, M., Meng, G., Pegram, M.D., Podratz, K.C., Crown, J., Slamon, D.J., Duffy, M.J.

“…Background: Survivin, a novel inhibitor of apoptosis, is one of the most cancer-specific proteins identified to date. In this study we (a) evaluated the…”
Get full text

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer by Konecny, G.E., Hendrickson, A.E. Wahner, Davidson, T.M., Winterhoff, B.J., Ma, S., Mahner, S., Sehouli, J., Fasching, P.A., Feisel-Schwickardi, G., Poelcher, M., Roman, L.D., Rody, A., Karlan, B.Y., Mullany, S.A., Chen, H., Ray-Coquard, I.L., Provencher, D.M., Yachnin, A., Cottu, P.H., Glaspy, J.A., Haluska, P., Slamon, D.J.

“…Insulin-like growth factor (IGF) signaling is implicated in pathogenesis and chemotherapy resistance of epithelial ovarian cancer (EOC). We explored efficacy…”
Get full text

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer by EBELING, F. G, STIEBER, P, UNTCH, M, NAGEL, D, KONECNY, G. E, SCHMITT, U. M, FATEH-MOGHADAM, A, SEIDEL, D

“…In the present study, we investigated the association of the serum levels of the tumour markers carcinoembryonic antigen and cancer antigen 15-3 with disease…”
Get full text

THE STATUS OF TOPOGRAPHIC MAPPING IN THE WORLD A UNGGIM–ISPRS PROJECT 2012–2015 by Konecny, G., Breitkopf, U., Radtke, A.

“…In December 2011, UNGGIM initiated a cooperative project with ISPRS to resume the former UN Secretariat studies on the status of topographic mapping in the…”
Get full text

Dose-dense Intensified Sequential Versus Conventionally-dosed Anthracycline and Taxane-containing Neoadjuvant Therapy in Patients with Inflammatory Breast Cancer by DITSCH, N, VODERMAIER, A, KONECNY, G. E, LOIBL, S, VON MINCKWITZ, G, UNTCH, M, HINKE, A, BURGHARDT, S, LENHARD, M, LÖHRS, B, TOTH, B, VON KOCH, F, KAHLERT, S, BAUERFEIND, I

“…This post-hoc analysis aimed to compare an intense dose-dense sequential chemotherapy (DD-CT) and a conventionally-dosed chemotherapy (CD-CT) in the…”
Get full text

Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer by Pegram, Mark D., Konecny, Gottfried E., O'Callaghan, Carminda, Beryt, Malgorzata, Pietras, Richard, Slamon, Dennis J.

“…Background: Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers…”
Get full text

2700 Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis by Kristeleit, R, Swisher, E, Oza, A, Coleman, R.L, Scott, C, Konecny, G, Tinker, A, O'Malley, D.M, Brenton, J, Bell-McGuinn, K, Oaknin, A, Leary, A, Lin, K.K, Raponi, M, Giordano, H, Maloney, L, Goble, S, Yelensky, R, McNeish, I

Get full text

215 Updated clinical and preliminary correlative results of ARIEL2, a Phase 2 study to identify ovarian cancer patients likely to respond to rucaparib by Swisher, E, Brenton, J, Kaufmann, S, Oza, A, Coleman, R.L, O'Malley, D, Konecny, G, Ma, L, Harrell, M, Visscher, D, Hendrickson, A.W, Lin, K, Raponi, M, Mann, E, Giordano, H, Maloney, L, Rolfe, L, McNeish, I

Get full text

Trastuzumab and chemotherapeutics: drug interactions and synergies by Pegram, M D, Lopez, A, Konecny, G, Slamon, D J

“…Previous studies have shown a synergistic interaction between trastuzumab (Herceptin; Genentech, Inc, South San Francisco, CA) and the cytotoxic drug cisplatin…”
Get more information